FDA Adds Warning to Osteoporosis Drug for Hypocalcemia Risk FDA Adds Warning to Osteoporosis Drug for Hypocalcemia Risk
Based on a completed data review, the agency concluded that denosumab increases the risk for severe hypocalcemia in patients with chronic kidney disease.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Nephrology Source Type: news
More News: Chronic Kidney Disease | Internal Medicine | Orthopaedics | Osteoporosis | Urology & Nephrology | Warnings | Xgeva